Michael D Bell1, Faysal A Yafi1, Fadi Brimo1,2, Jordan Steinberg1, Armen G Aprikian1, Simon Tanguay1, Wassim Kassouf3. 1. Department of Surgery (Urology), McGill University, Montreal, QC, Canada. 2. Division of Pathology, McGill University Health Center, Montreal, QC, Canada. 3. Department of Surgery (Urology), McGill University, Montreal, QC, Canada. wassim.kassouf@muhc.mcgill.ca.
Abstract
PURPOSE: Urinary cytology (C) and cystoscopy remain the gold standard for the detection and screening of bladder cancer (BC). In this prospective study, we analyzed whether baseline C, ImmunoCyt (I), BTA Stat (B), hemoglobin dipstick (H), and NMP22 BladderChek (N) can predict recurrence and progression. METHODS: Urinary samples from 91 patients with BC were prospectively collected over an 18-month period. Baseline characteristics of the population included patient demographics, various clinicopathological variables and use of intravesical therapy. Progression and recurrence were then assessed after a median follow-up of 48 months (IQR 23.7-59.5). Univariate and multivariate analyses were performed using COX proportional hazards models. RESULTS: On univariate analysis, C (HR 1.36; p = 0.26), I (HR 0.89; p = 0.66), B (HR 0.80; p = 0.42), H (HR 0.75; p = 0.30), and N (HR 0.82; p = 0.48) were not associated with recurrence-free survival (RFS). With regard to progression-free survival (PFS), C was significantly prognostic (HR 2.67; p = 0.017), whereas I, B, H, and N were not. On multivariable analysis, NMP22 was the only marker to be independently associated with RFS (HR 0.41, p < 0.01) and PFS (HR 0.32, p = 0.02). CONCLUSION: Based on the results of this study, baseline C, B, I, and H were not independently prognostic. Prognostic impact of NMP22 requires further validation in a multicenter larger study.
PURPOSE: Urinary cytology (C) and cystoscopy remain the gold standard for the detection and screening of bladder cancer (BC). In this prospective study, we analyzed whether baseline C, ImmunoCyt (I), BTA Stat (B), hemoglobin dipstick (H), and NMP22 BladderChek (N) can predict recurrence and progression. METHODS: Urinary samples from 91 patients with BC were prospectively collected over an 18-month period. Baseline characteristics of the population included patient demographics, various clinicopathological variables and use of intravesical therapy. Progression and recurrence were then assessed after a median follow-up of 48 months (IQR 23.7-59.5). Univariate and multivariate analyses were performed using COX proportional hazards models. RESULTS: On univariate analysis, C (HR 1.36; p = 0.26), I (HR 0.89; p = 0.66), B (HR 0.80; p = 0.42), H (HR 0.75; p = 0.30), and N (HR 0.82; p = 0.48) were not associated with recurrence-free survival (RFS). With regard to progression-free survival (PFS), C was significantly prognostic (HR 2.67; p = 0.017), whereas I, B, H, and N were not. On multivariable analysis, NMP22 was the only marker to be independently associated with RFS (HR 0.41, p < 0.01) and PFS (HR 0.32, p = 0.02). CONCLUSION: Based on the results of this study, baseline C, B, I, and H were not independently prognostic. Prognostic impact of NMP22 requires further validation in a multicenter larger study.
Authors: Maximilian Burger; James W F Catto; Guido Dalbagni; H Barton Grossman; Harry Herr; Pierre Karakiewicz; Wassim Kassouf; Lambertus A Kiemeney; Carlo La Vecchia; Shahrokh Shariat; Yair Lotan Journal: Eur Urol Date: 2012-07-25 Impact factor: 20.096
Authors: Shahrokh F Shariat; Caroline Savage; Thomas F Chromecki; Maxine Sun; Douglas S Scherr; Richard K Lee; Giovanni Lughezzani; Mesut Remzi; Michael J Marberger; Pierre I Karakiewicz; Andrew J Vickers Journal: Cancer Date: 2011-01-10 Impact factor: 6.860
Authors: Michael S Kent; Allison Zwingenberger; Jodi L Westropp; Laura E Barrett; Blythe P Durbin-Johnson; Paramita Ghosh; Ruth L Vinall Journal: BMC Vet Res Date: 2017-11-15 Impact factor: 2.741
Authors: Francesco Soria; Michael J Droller; Yair Lotan; Paolo Gontero; David D'Andrea; Kilian M Gust; Morgan Rouprêt; Marek Babjuk; Joan Palou; Shahrokh F Shariat Journal: World J Urol Date: 2018-06-21 Impact factor: 4.226